⚠
NIOSH Table 1 Hazardous DrugsAll cytotoxic agents are classified as hazardous drugs. They carry risks of carcinogenicity, teratogenicity, reproductive toxicity, organ toxicity, and genotoxicity. Special handling is mandatory for all healthcare workers.
Cytotoxic Mechanisms by Drug Class
Alkylating Agents
DNA Cross-Linking
- Cyclophosphamide, Ifosfamide, Chlorambucil, Melphalan
- Mechanism: Covalent DNA cross-links — prevent replication
- Key toxicity: Haemorrhagic cystitis (cyclophosphamide/ifosfamide) — acrolein metabolite
- Mesna prophylaxis mandatory for ifosfamide and high-dose cyclophosphamide
- Mesna given at 0h, 4h, 8h post-dose (or continuous infusion per protocol)
- Ensure adequate hydration; monitor urine for haematuria
Antimetabolites
Nucleotide Analogues / Enzyme Inhibitors
- Methotrexate: Folate antagonist — folinic acid (leucovorin) rescue mandatory for high-dose regimens; monitor methotrexate levels
- 5-FU / Capecitabine: Thymidylate synthase inhibition — DPD deficiency testing mandatory before prescribing (DPYD gene testing) — deficiency = severe life-threatening toxicity
- Cytarabine: Ara-CTP incorporation — cerebellar toxicity at high dose
- Gemcitabine: Ribonucleotide reductase inhibition — monitor FBC
Anthracyclines
Topoisomerase II Inhibition / Free Radical Generation
- Doxorubicin, Epirubicin
- Cumulative cardiotoxicity: dilated cardiomyopathy
- Doxorubicin lifetime max: 450–550 mg/m²
- ECHO (echocardiogram) monitoring: baseline + at cumulative dose thresholds
- Red/pink urine: normal discolouration — warn patient; does not indicate haematuria
- Severe vesicant: extravasation = tissue necrosis
Taxanes
Microtubule Stabilisation
- Paclitaxel, Docetaxel
- Prevents mitotic spindle disassembly — cell cycle arrest
- Hypersensitivity premedication ESSENTIAL — dexamethasone + antihistamine + H2 blocker before each cycle
- Paclitaxel: Cremophor EL vehicle — anaphylaxis risk; infuse slowly with nurse present
- Peripheral neuropathy: cumulative, dose-limiting
- Docetaxel: fluid retention syndrome — dexamethasone pre-treatment reduces severity
Vinca Alkaloids
Microtubule Depolymerisation
- Vincristine, Vinblastine
- NEVER INTRATHECAL = FATAL — ascending paralysis, death
- Must be dispensed in minibag (NOT syringe) to prevent intrathecal confusion
- Peripheral neuropathy: dose-limiting toxicity for vincristine
- Constipation: prophylactic laxatives mandatory — may progress to paralytic ileus
- Vinblastine: bone marrow suppression more prominent
Platinum Agents
DNA Adduct Formation
- Cisplatin: Nephrotoxicity — pre/post hydration mandatory (1–2L saline before and after); monitor creatinine/eGFR; ototoxicity (high-frequency hearing loss — audiometry baseline); severe nausea/vomiting (highly emetogenic)
- Carboplatin: AUC-based dosing (Calvert formula: dose = AUC × [GFR + 25]); major toxicity = thrombocytopenia; less nephrotoxic than cisplatin
- Oxaliplatin: Peripheral neuropathy — cold-induced (acute) and cumulative sensory
Topoisomerase Inhibitors
DNA Strand Break Induction
- Irinotecan (CPT-11): Topoisomerase I inhibitor — UGT1A1 testing before use; *28 allele = reduced SN-38 metabolism = severe toxicity; biphasic diarrhoea (early cholinergic + delayed)
- Etoposide: Topoisomerase II inhibitor; secondary leukaemia risk (long-term); myelosuppression
NIOSH Table 1 — Hazardous Drug Summary
Special Handling Required
- All antineoplastic agents meet NIOSH hazardous drug criteria
- Risk to reproductive system, fetus, and with long-term exposure: secondary malignancy
- Healthcare workers: pregnant or attempting pregnancy should avoid handling
- Closed system drug transfer devices (CSTDs) required for all preparation and IV administration
- Dedicated chemotherapy-certified nurses and pharmacists only
📋
Key Pharmacogenomics in GCC PracticeDPD deficiency (DPYD variants): affects fluoropyrimidine metabolism — test before 5-FU/capecitabine. UGT1A1*28: affects irinotecan detoxification — test before irinotecan. Both tests improve patient safety and reduce severe or fatal toxicity.
⚠
NIOSH Hazardous Drug Handling GuidelinesAll healthcare workers handling cytotoxic drugs must follow NIOSH guidelines. Exposure routes: dermal absorption, inhalation of aerosols/dust, ingestion, needlestick. Pregnant staff must not handle cytotoxics.
Required PPE by Task
| PPE Item | Specification | When Required |
|---|
| Gloves (outer) | Chemotherapy-rated nitrile, ≥0.1 mm thick, tested for permeability to chemotherapy agents (ASTM D6978) | ALL handling tasks |
| Gloves (inner) | Latex-free, powder-free; double-gloving mandatory | ALL handling tasks |
| Gown | AAMI Level 3 protection; non-permeable polyethylene-coated; long sleeves, tight cuffs, tie at back — NOT front-opening | All preparation and administration |
| Eye/face protection | Safety goggles or face shield | Opening vials, connecting/disconnecting IV lines, any splash risk |
| Respiratory protection | N95 respirator (fit-tested); surgical mask insufficient | If aerosolisation possible (e.g., crushing tablets, spill, outside BSC) |
| Shoe covers | If spill risk or large volumes | Major spill response |
🏭Biological Safety Cabinet (BSC)
Class II Type B2 preferred for chemotherapy preparation — all exhaust externally vented, no air recirculation.
Class II Type A2 also acceptable with HEPA filtration.
Negative pressure workspace protects preparer from drug exposure. HEPA filter captures particles ≥0.3 micron.
BSC certification: every 6 months minimum. Do not use BSC if alarm is sounding or certification expired.
All cytotoxic preparation must occur in certified BSC in pharmacy — never on ward.
🔗Closed System Drug Transfer Devices (CSTDs)
Mechanical systems that prevent escape of hazardous drug vapour or liquid during transfer.
Examples: PhaSeal, TEVADAPTOR, BD Onguard, Equashield
Mandatory for: vial reconstitution, syringe drawing, IV bag preparation, connecting/disconnecting IV administration sets.
Reduce measurable surface contamination by 75–99% compared to open systems.
Check compatibility: not all CSTDs are compatible with all drug formulations or containers.
IV Administration Safety
Before Connecting
- IV set primed by pharmacy (never prime on ward — exposure risk)
- Don double gloves and gown before handling
- Inspect bag/syringe for particulate, cloudiness, leaks
- Check label against prescription — independent double check
- Confirm IV access patent: flush with sodium chloride 0.9%
- Use CSTD for all connections
During & After Administration
- Monitor site: check every 15–30 min for vesicants
- Check for line patency: blood return before and during infusion for vesicants
- Do not cap unused ports without Luer-lock protection
- After disconnecting: cap and seal in cytotoxic waste bag
- All waste (tubing, bags, gloves, gowns): into yellow cytotoxic waste bags
- Sharps: cytotoxic-rated sharps container
- Remove PPE: outer gloves first, then gown, then inner gloves; wash hands
Oral Cytotoxic Drug Handling
Oral Chemotherapy — Nurse & Patient/Carer Precautions
Healthcare Worker
- Double gloves when handling tablets/capsules
- Do not crush or split unless specifically licensed for that formulation
- If crushing required: N95 respirator + face shield + BSC or ventilated enclosure
- Use unit-dose dispensing where possible
Patient/Carer Education
- Handle with gloves (disposable) or wash hands thoroughly after
- Keep in original childproof container — separate from household medicines
- Do not store in kitchen/fridge with food items
- Return unused tablets to pharmacy — do not flush or bin
- Bodily fluids hazardous for 48–72h — wear gloves for cleaning
✓
Chemotherapy Nurse Competency RequirementOnly nurses who have completed a formal chemotherapy administration competency programme (theory + supervised practice) may administer cytotoxic drugs. Competency must be documented and renewed as per institutional/national policy (typically every 2 years). This is a requirement under DHA, DOH Abu Dhabi, SCFHS, and CBAHI standards.
Pre-Administration Verification — Independent Double Check
⚠
Two-Nurse Independent Double Check RequiredAll chemotherapy must be verified by two registered nurses (both chemotherapy-competent) before administration. Checks must be independent — the second nurse does not simply agree with the first.
| # | Verification Item | How to Verify |
|---|
| 1 | Right Patient — 3 Identifiers | Full name + date of birth + MRN — verbal confirmation + wristband match + ask patient to state name |
| 2 | Right Drug | Generic AND brand name — match label to prescription/EPR |
| 3 | Right Dose | mg/m² or AUC calculation verified — BSA/weight current and documented |
| 4 | Right Route | IV peripheral / IV central / oral / intrathecal — confirm against protocol |
| 5 | Right Rate & Time | Infusion duration and rate as prescribed; cycle day and time |
| 6 | Allergies | Allergy band visible; EPR allergies reviewed; previous hypersensitivity documented |
| 7 | Consent | Signed informed consent in notes — patient understands treatment and side effects |
| 8 | Blood Results | Within protocol-specified window (usually 7 days): ANC ≥1.0 × 10⁹/L, Platelets ≥100 × 10⁹/L, LFTs, renal function per protocol thresholds |
| 9 | Cycle Number & Day | Matches protocol — correct cycle number and day within cycle (e.g., Day 1 of Cycle 3) |
| 10 | Previous Toxicities | Review prior cycle toxicity — dose reductions or delays indicated |
| 11 | IV Access | Central or peripheral — patent, no signs of phlebitis/infection; blood return confirmed for vesicants |
| 12 | Antidote/Emergency | Antidote available if vesicant; resuscitation equipment accessible; anaphylaxis kit available for taxanes/platinum |
Administration Documentation Requirements
Mandatory Documentation per Administration
- Batch number and expiry date of each drug
- Time started and time completed
- Volume infused and rate
- IV site assessment (location, gauge, condition)
- Patient observations during infusion
- Any reactions, delays, or complications
- Premedications given (with times)
- Antiemetics given (with times)
- Both nurse signatures (double-check documented)
- Patient verbal/written tolerability at end of infusion
Vesicant Extravasation Management
⚠
Extravasation Emergency ProtocolVesicant extravasation can cause severe tissue necrosis requiring surgical debridement or amputation. Act immediately.
- STOP infusion immediately — do not remove cannula
- Leave cannula in place — aspirate as much drug as possible through the cannula
- Do NOT flush with saline (disperses drug), do NOT apply pressure
- Administer antidote if available (see table below)
- Apply compress (see drug-specific guidance below)
- Elevate the affected limb above heart level
- Photograph site — document size, appearance
- Complete incident report / adverse event form immediately
- Refer to plastic surgery / wound care specialist promptly
- Provide written instructions and follow-up appointment for patient
| Drug/Class | Classification | Antidote | Compress |
|---|
| Doxorubicin, Epirubicin, Daunorubicin | Vesicant | Dexrazoxane IV (within 6h) OR DMSO topical | Cold compress (reduces absorption) |
| Vincristine, Vinblastine, Vinorelbine | Vesicant | Hyaluronidase subcutaneous injection around site | Warm compress (disperses drug) |
| Dacarbazine, Streptozocin | Vesicant | No specific antidote — manage conservatively | Cold compress |
| Cisplatin (>0.4mg/mL) | Irritant | Sodium thiosulphate injection around site | Cold compress |
| Etoposide, Docetaxel, Carboplatin | Irritant | Hyaluronidase considered (etoposide) | Cold compress |
| 5-Fluorouracil, Cyclophosphamide | Non-vesicant | Not required | Warm compress |
💬
Central Venous Access Preference for VesicantsStrongly recommended to administer vesicants via central venous access (PICC, port-a-cath, CVC) to minimise extravasation risk. Peripheral administration of vesicants requires freshly placed, large-gauge cannula with confirmed blood return, and close monitoring throughout infusion.
⚠
Oral Chemotherapy: Same Risk, Different SettingOral chemotherapy carries identical hazardous drug risks as IV formulations. Patient self-administration at home creates unique safety challenges. Errors in oral chemotherapy have caused patient deaths — systematic education and follow-up are essential.
High-Alert Oral Cytotoxic Drugs
Capecitabine (Xeloda)
Fluoropyrimidine — Oral 5-FU Prodrug
- Schedule: 14 days ON / 7 days OFF (most common)
- Dose: twice daily with food (within 30 min of meal)
- Key toxicities: HFS, diarrhoea, mucositis, fatigue
- DPD deficiency: test before starting
- Missed dose: skip — do NOT double up
- If vomiting after dose: do NOT re-dose that administration
- Warfarin interaction: INR monitoring required if on warfarin
Temozolomide (Temodar/Temodal)
Alkylating Agent — Oral
- Glioblastoma: concurrent with radiotherapy (75 mg/m²/day) then adjuvant (150–200 mg/m²/day D1–5 every 28 days)
- Must be taken fasting (empty stomach) or consistent timing
- Antiemetic prophylaxis: ondansetron before each dose
- PCP prophylaxis: co-trimoxazole (Septrin) during concurrent phase
- Lymphocyte monitoring: lymphopaenia common
- Capsules must not be opened
Methotrexate — Low Dose Weekly
Antimetabolite — Critical Prescribing Alert
- FATAL ERROR RISK: Weekly dosing — if given daily = fatal toxicity
- Folic acid 5mg supplementation on non-methotrexate days
- Monitor: FBC, renal, LFTs every 6–12 weeks
- Interactions: NSAIDs, trimethoprim, penicillins — raise methotrexate levels
- Patient must know: weekly dose only — clear written instructions
Targeted Oral Agents
Tyrosine Kinase Inhibitors / mTOR Inhibitors
- Imatinib/Gleevec: CML — with food; drug interactions (CYP3A4)
- Lapatinib: HER2+ BC — cardiac monitoring, diarrhoea, fasting 1h before/1h after
- Everolimus: mTOR inhibitor — stomatitis (steroid mouth rinse, not antifungal), immunosuppression, hyperglycaemia
- Sorafenib/Sunitinib: RCC, HCC — HFS, hypertension monitoring, thyroid function
Patient Education Framework — Oral Chemotherapy
The 6-Domain Education Model
1. Dose & Schedule
- Written schedule with clear dosing times
- Continuous vs intermittent cycle explanation
- What to do if a dose is missed (drug-specific)
- What to do if vomiting occurs after taking dose
2. Safe Handling at Home
- Wear disposable gloves when handling
- Childproof container, away from food/kitchen
- Keep away from children and pets
- Return unused drugs to pharmacy
3. Side Effect Monitoring
- Drug-specific toxicity signs — when to call
- Symptom diary or mobile tracking app
- 24h oncology helpline number
4. Adherence Support
- Pill diary / mobile app (Mediteo, Medisafe)
- Carer/support person engagement
- Pharmacy reminders or blister packs
- Non-adherence = treatment failure — emphasise importance
5. Drug Interactions
- OTC medications (antacids, St John's Wort)
- Herbal/traditional remedies — high risk in GCC
- Grapefruit juice: avoid with many TKIs (CYP3A4)
- Always inform pharmacist before new medication
6. Disposal & Bodily Fluids
- Urine/faeces hazardous for 48h
- Flush toilet twice; wear gloves for linen handling
- Sexual relations: barrier contraception during/after treatment
- Contraception essential — teratogenic risk
⚠
GCC Context — Oral Chemotherapy MonitoringHistorically, community-based follow-up for oral chemotherapy has been limited across GCC. Growing cancer nursing services (nurse-led telephone clinics, clinical pharmacist review, digital platforms) are now being implemented at KFSH&RC, NCCO Oman, Qatar NCC, and Cleveland Clinic Abu Dhabi. All patients must be given a 24h oncology emergency contact number.
GCC Oncology Services Overview
Major GCC Cancer Centres
- KFSH&RC (Saudi Arabia): King Faisal Specialist Hospital & Research Centre — Riyadh & Jeddah; tertiary oncology reference centre
- National Oncology Centre (NOC), Oman: Muscat — dedicated cancer centre with bone marrow transplant unit
- Qatar National Cancer Centre (QNCC): Hamad Medical Corporation, Doha
- Cleveland Clinic Abu Dhabi (CCAD): Oncology Institute with US-standard protocols
- Tawam Hospital, UAE: National cancer centre affiliate of Johns Hopkins
- Kuwait Cancer Control Centre: Established tertiary oncology services
Regulatory & Nursing Standards Bodies
- DHA (Dubai Health Authority): Chemotherapy nurse competency framework, medication safety standards
- DOH Abu Dhabi: Hazardous drug handling policy, oncology nursing scope
- SCFHS (Saudi Commission): Oncology nursing specialty classification, exam board
- CBAHI: Hospital accreditation — chemotherapy safety standards
- JCI Accreditation: International standards for medication management and hazardous drugs
Cytotoxic Spill Kit — Contents & Management
⚠
Spill Kit Required on Every Chemotherapy WardA complete cytotoxic spill kit must be immediately accessible on all wards where chemotherapy is administered or stored. All staff must know its location and how to use it.
🧦
Double gloves (chemo-rated)
👁
Safety goggles / face shield
🧸
Absorbent granules / powder
⚠
Warning sign / barrier tape
🛒
Cleaning solution (water/detergent)
Spill Management — Step-by-Step
- Alert others — limit access to spill area; place warning sign
- Don full PPE: double gloves, gown, eye protection, N95 respirator
- Apply absorbent granules/powder to liquid spills (working from outside inward)
- Use plastic scoop (never bare hands) to collect contaminated material
- Seal waste in inner cytotoxic bag, then seal in outer cytotoxic bag
- Clean area three times with water and detergent (cytotoxic contamination is not removed by alcohol alone)
- Place all PPE and cleaning materials into cytotoxic waste bags
- Wash hands thoroughly with soap and water
- Document incident: time, drug, volume, persons involved, actions taken
- Refer exposed staff to occupational health immediately
MCQ Practice — Chemotherapy Safety
Click on the answer option you believe is correct. Immediate feedback with explanation provided.
Question 1 of 10
A patient is receiving vincristine. You notice it has been prepared in a 5mL syringe. What is the MOST appropriate action?
A. Administer it as prepared — small volume drugs often come in syringes
B. Return to pharmacy — vincristine must be dispensed in a minibag, not syringe
C. Dilute the syringe contents with saline before administering
D. Administer via IV push only — syringes are faster
Vinca alkaloids, especially vincristine, must be dispensed in minibags (≥50mL) specifically to prevent accidental intrathecal administration. Intrathecal vinca alkaloids cause ascending paralysis and death. This is an international patient safety goal.
Question 2 of 10
Which antidote is correct for anthracycline (doxorubicin) extravasation?
A. Hyaluronidase subcutaneous injections around the site
B. Sodium thiosulphate infiltration
C. Dexrazoxane IV within 6 hours OR topical DMSO
D. No antidote available — immediate surgery only
Dexrazoxane (Savene/Totect) given IV within 6 hours is the preferred antidote for anthracycline extravasation. Topical DMSO (99%) applied to the affected area every 8 hours for 7 days is an alternative. Hyaluronidase is used for vinca alkaloid extravasation. Warm compress is used for vinca alkaloids; cold compress for anthracyclines.
Question 3 of 10
A patient receiving cisplatin develops urine output of only 40mL/hour during the infusion. What is the PRIORITY nursing action?
A. Increase IV fluid rate and notify the prescriber — target output ≥100mL/h
B. Continue cisplatin — low urine output is expected and acceptable
C. Stop the infusion and insert a urinary catheter
D. Administer furosemide 40mg IV without consulting the prescriber
Cisplatin is nephrotoxic; adequate hydration and urine output ≥100mL/hour during cisplatin infusion are essential to prevent tubular damage. Low urine output (40mL/h) requires immediate escalation and increasing IV fluids. Never administer furosemide without medical order in this context.
Question 4 of 10
What is the correct compress to apply immediately after vinca alkaloid (vincristine) extravasation?
A. Warm compress — promotes vasodilation and drug dispersal
B. Cold compress — reduces drug absorption
C. No compress needed — only antidote is required
D. Alternating warm and cold every 5 minutes
Warm compress is applied for vinca alkaloid extravasation — it promotes vasodilation and dispersion of the drug away from the localised site, reducing tissue damage. Cold compress is used for anthracyclines. Hyaluronidase SC infiltration is the antidote of choice for vinca alkaloids.
Question 5 of 10
A patient on capecitabine develops red, painful, blistering skin on palms and soles after Cycle 1. This is most consistent with:
A. Allergic contact dermatitis from IV chemotherapy
B. Chemotherapy-induced peripheral neuropathy
C. Hand-Foot Syndrome (Palmar-Plantar Erythrodysaesthesia)
D. Paronychia from taxane therapy
Hand-Foot Syndrome (HFS / PPE) is a hallmark toxicity of capecitabine. Blistering suggests Grade 2 HFS, requiring dose hold until recovery to ≤Grade 1. Management includes emollient creams (urea-based), avoidance of pressure, cool soaks, and patient education. Subsequent cycles require dose reduction.
Question 6 of 10
Which glove standard is required for cytotoxic drug handling?
A. Standard clinical nitrile gloves (any thickness)
B. Chemotherapy-tested nitrile gloves meeting ASTM D6978, with double-gloving
C. Sterile latex surgical gloves — single layer is sufficient
D. Vinyl gloves are acceptable for all cytotoxic handling tasks
NIOSH guidelines require gloves tested to ASTM D6978 (chemotherapy permeability standard). Double-gloving is mandatory. Vinyl gloves are NOT acceptable — they have poor permeation resistance to chemotherapy agents. Latex gloves carry allergy risk and are being phased out. Minimum outer glove thickness: 0.1mm for chemotherapy-rated nitrile.
Question 7 of 10
A patient receiving irinotecan develops acute abdominal cramps, profuse sweating, and lacrimation during the infusion. What is the MOST appropriate treatment?
A. Loperamide 4mg immediately
B. Atropine 0.25–1mg IV or SC
C. Stop irinotecan permanently — anaphylaxis suspected
D. Metoclopramide 10mg IV
These symptoms represent early/acute cholinergic diarrhoea from irinotecan — caused by inhibition of acetylcholinesterase. Treatment: atropine 0.25–1mg IV or SC. Loperamide is used for DELAYED diarrhoea (onset after 24h). Prophylactic atropine can be given before irinotecan infusion in patients who experienced early diarrhoea in prior cycles.
Question 8 of 10
A patient on doxorubicin-based chemotherapy asks why their urine is pink/red. What is the correct response?
A. "This indicates kidney damage — stop your fluids and call emergency services"
B. "This is a normal, expected drug effect that can last 1–2 days — it is the drug being excreted and is not blood in the urine"
C. "You should come to the hospital immediately for urinalysis"
D. "Stop taking all your medications until this resolves"
Doxorubicin (and epirubicin) cause pink/red urine for 1–2 days after administration. This is a NORMAL drug effect due to excretion of the red-coloured drug. Patients must be warned about this prior to receiving anthracyclines to prevent alarm. True haematuria would be investigated separately based on symptoms and urinalysis.
Question 9 of 10
Before administering paclitaxel, which premedication regimen is essential?
A. Metoclopramide + ranitidine only — to prevent nausea
B. Dexamethasone + H1 antihistamine (diphenhydramine) + H2 blocker (ranitidine/famotidine) — hypersensitivity prophylaxis
C. No premedication needed if patient has no known allergies
D. Ondansetron + lorazepam — to prevent anticipatory nausea only
Paclitaxel is formulated in Cremophor EL (polyoxyethylated castor oil) which causes severe hypersensitivity reactions. Premedication with dexamethasone (12–20mg IV), diphenhydramine (50mg IV), and an H2 blocker (ranitidine 50mg or famotidine 20mg) is mandatory before EVERY cycle. Nab-paclitaxel (Abraxane) has different premedication requirements.
Question 10 of 10
The minimum acceptable ANC (absolute neutrophil count) before most chemotherapy cycles can proceed is:
A. 0.5 × 10⁹/L
B. 1.0 × 10⁹/L
C. 1.5 × 10⁹/L
D. 2.0 × 10⁹/L
The widely accepted threshold is ANC ≥1.0 × 10⁹/L before proceeding with most chemotherapy regimens. Platelets ≥100 × 10⁹/L is the typical platelet threshold. Some protocols specify ANC ≥1.5 for certain regimens — always check the specific protocol. If thresholds are not met, chemotherapy is delayed and the patient is reassessed.
Interactive Tool — Pre-Administration Safety Checklist